PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
34.62%
G&A change of 34.62% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
14.45%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
14.45%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
561.32%
Interest expense change of 561.32% while TRAW maintains costs. Bruce Berkowitz would investigate control.
-26.41%
Both companies reducing D&A. Martin Whitman would check industry patterns.
55.40%
EBITDA growth exceeding 1.5x TRAW's 7.63%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Operating income decline while TRAW shows 7.56% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
43.33%
Pre-tax income growth exceeding 1.5x TRAW's 7.52%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense growth while TRAW reduces burden. John Neff would investigate differences.
43.33%
Net income growth exceeding 1.5x TRAW's 7.70%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth exceeding 1.5x TRAW's 7.72%. David Dodd would verify competitive advantages.
43.35%
Diluted EPS growth exceeding 1.5x TRAW's 7.72%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.